{"prompt": "['3.0', 'PARTICIPANT SELECTION', 'A CTEP-registered investigator (Dr. Nestory Masalu or Dr. Kristin Schroeder) will', 'document that each protocol participant meets all stated eligibility criteria. Satisfaction of', 'eligibility requirement will be documented prior to participant enrollment. In compliance', 'with CTEP policy, no exceptions to eligibility criteria will be granted under any', 'circumstance.', 'NOTE: Institutions may use this section of the protocol as an eligibility checklist for source', 'documentation if it has been reviewed, signed, and dated before registration/randomizatior', 'by the study investigator. If used as source documentation, this checklist must be printed,', 'the investigator must check each item to document their assessment that the participant', 'meets each eligibility criterion, and the completed checklist must be maintained in the', \"participant's chart.\", 'Participant ID Number: S007-', \"Patient's Initials (L, F, M):\", '3.1', 'Eligibility Criteria', '3.1.1 HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or', 'chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry', 'and confirmed by a licensed Western blot or a second antibody test by a method', 'other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1', 'RNA viral load.', 'NOTE: The term \"licensed\" refers to a U.S. FDA-approved kit or for sites located', 'in countries other than the U.S., a kit that has been certified or licensed by an', 'oversight body within that country and validated internally.', 'World Health Organization (WHO) and Centers for Disease Control and Prevention', '(CDC) guidelines mandate that confirmation of the initial test result must use a test', 'that is different from the one used for the initial assessment. A reactive initial rapid', 'test should be confirmed by either another type of rapid assay or an E/CIA that is', 'based on a different antigen preparation and/or different test principle (e.g., indirect', 'versus competitive), or a Western blot or a plasma HIV-1 ribonucleic acid (RNA)', 'viral load.', '3.1.2', 'Participants must have pathologically confirmed Kaposi sarcoma.', '3.1.3 Participants should not have had prior therapy for their Kaposi sarcoma.', '3.1.4 All participants must be on stable antiretroviral therapy (ART) for a minimum of', '12 weeks prior to study entry with an acceptable regimen that adheres to national', 'guidelines for treatment of HIV infection.', '3.1.5 Age >18 years. Because no dosing or adverse event data are currently available on', 'the use of BV in participants <18 years of age, children are excluded from this', 'study.', '3.1.6 ECOG performance status 2 (Karnofsky performance status > 50%, see Appendix', 'II).', 'AMC-S007 (Version 2.0) 20MAR2018', '14', 'NCI Version Date 20MAR2018']['3.1.7', 'Participants must have organ and marrow function within the following parameters', 'within 7 days of enrollment:', 'Leukocytes: > 3,000/mm\u00b3', 'Absolute neutrophil count: > 1,000/mm\u00b3', 'Hemoglobin > 8 g/dL', 'Platelets: > 75,000/mm\u00b3', 'Direct bilirubin: < 3mg/dL', 'AST (SGOT) / ALT (SGPT): 2.5 X institutional upper limit of normal', 'Creatinine:', 'Creatinine levels within normal institutional limits; or,', 'Creatinine clearance > 60 mL/min/1.73 m\u00b2 for participants with creatinine', 'levels above institutional normal', '3.1.8 Participants with serious chronic, acute, or recurrent infections must have', 'completed at least 14 days of therapy prior to enrollment and be clinically stable.', '3.1.9', 'If the participant is a female of childbearing potential (FCBP), defined as a sexually', 'mature woman who: (1) has not undergone a hysterectomy or bilateral', 'oophorectomy, or (2) has not been naturally postmenopausal for at least 24', 'consecutive months (i.e., has had menses at any time in the preceding 24', 'consecutive months), the participant must have a negative urine or serum pregnancy', 'test within 1 week prior to enrollment and agree to use an effective form of', 'contraception (e.g., barrier contraception or hormonal contraception), during the 5', 'months of planned chemotherapy treatment and for 6 months after completing', 'treatment.', '3.1.10 Ability to understand and the willingness to sign a written informed consent', 'document.', '3.2', 'Exclusion Criteria', 'Participants who do not fulfill the criteria as listed in Section 3.1 above, are ineligible.', 'Additionally, the presence of any of the following conditions will exclude a participant', 'from study enrollment:', '3.2.1 Participants who are receiving any other investigational agents.', '3.2.2 Participants with known brain metastases should be excluded from this clinical trial', 'because of their poor prognosis and because they often develop progressive', 'neurologic dysfunction that would confound the evaluation of neurologic and other', 'adverse events.', '3.2.3 History of allergic reactions attributed to compounds of similar chemical or', 'biologic composition to bleomycin or vincristine.', '3.2.4 Uncontrolled intercurrent illness including, but not limited to, ongoing or active', 'infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac', 'arrhythmia, or psychiatric illness/social situations that would limit compliance with', 'study requirements.', '3.2.5 Participants who are breastfeeding a child. Because there is an unknown but', 'AMC-S007 (Version 2.0) 20MAR2018', '15', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}